Cellectis S.A. Share Price & Technical Analysis
CLLS · $3.50 (-1.13%)
Healthcare / Biotechnology
$3.50
-1.13%
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasm…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-12% return in May, -2% avg return in past 3 year May month.
-34% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -21% | 3% | -18% | 15% | -12% | – | – | – | – | – | – | – | -34% |
| 25 | -11% | -13% | -14% | 33% | -6% | 0% | 67% | -13% | 8% | 17% | 55% | -2% | 119% |
| 24 | 0% | -13% | 4% | 0% | 4% | -30% | 16% | 9% | -9% | -14% | 17% | -10% | -27% |
| 23 | 30% | -27% | -14% | -5% | -5% | 5% | 11% | 0% | -20% | -37% | 11% | 7% | -44% |
| 22 | -27% | -33% | 2% | -24% | 3% | -20% | -7% | 18% | -28% | 9% | -12% | -5% | -124% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$396.47M
P/E ratio
—
52W high
$5.48
52W low
$1.33
Volume
13,405
Beta
2.72
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cellectis S.A. share price today?
- Cellectis S.A. (CLLS) last traded around $3.50 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CLLS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CLLS. Download the app for real-time alerts.
- How can I analyze Cellectis S.A. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.